Test Price
2,800 AED✅ Home Collection Available
SLC12A5 Gene Bartter Syndrome Genetic Test in UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Next‑Generation Sequencing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post‑Test Clinical Interpretation with a DHA‑Licensed Medical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The SLC12A5 Gene Bartter Syndrome Genetic Test is a comprehensive next‑generation sequencing assay that analyses the entire coding region of the SLC12A5 gene to diagnose Bartter syndrome type 3, a hereditary renal salt‑wasting disorder. This test is essential for patients with hypokalemic metabolic alkalosis, hyperreninemic hyperaldosteronism, and a family history suggestive of the condition. Pre‑test genetic counselling with a detailed pedigree chart is required.
| Feature | Our Test (NGS) | Closest Alternative (Single‑Gene Sanger) |
|---|---|---|
| Precision | 99.9% analytical sensitivity for all coding variants | Limited to known hotspots; may miss deep intronic/non‑coding changes |
| Method | Next‑Generation Sequencing (Illumina platform) with Sanger confirmation | Bidirectional Sanger sequencing of selected exons |
| Turnaround | 3–4 Weeks | 2–3 Weeks (but less comprehensive) |
Physician Insight & Safety Protocols
“As a DHA‑licensed consultant medical geneticist, I emphasise that a positive SLC12A5 result confirms the molecular aetiology of Bartter syndrome type 3. However, correlation with serum electrolytes, blood gas analysis, and full clinical context is mandatory. This test provides clarity for lifelong management and family counselling. Bear in mind that a negative result does not exclude other subtypes or phenocopies.”
Advisory – Medication Warning
Do not discontinue prescribed potassium supplements, diuretics, or any other medication without consulting your treating physician. Abrupt cessation can provoke severe hypokalemia or arrhythmia.
Exclusion Criteria & Red Flags
- Patient unwilling or unable to undergo genetic counselling and provide a three‑generation pedigree.
- Acute hemodynamic instability, severe electrolyte crisis (K+ <2.5 mmol/L, cardiac arrhythmia), or signs of volume depletion requiring emergency care.
- Inability to provide venous blood or an FTA card sample (e.g., extreme thrombocytopenia, active systemic infection).
If you experience severe muscle weakness, palpitations, fainting, or irregular heartbeat prior to sample collection, proceed to the nearest emergency department immediately.
Patient FAQ & Clinical Guidance
1. What is the purpose of the SLC12A5 genetic test?
The SLC12A5 gene test definitively diagnoses Bartter syndrome type 3 by identifying disease‑causing mutations in the renal thiazide‑sensitive sodium‑chloride cotransporter gene. This allows families to receive accurate prognostication, tailored electrolyte management, and prenatal counselling options. The test is recommended for infants and children presenting with failure to thrive, polyuria, and low‑normal blood pressure alongside hypokalemic metabolic alkalosis.
2. How is the sample collected and what is the turnaround time?
A simple venous blood draw, a one‑drop blood sample on an FTA card, or previously extracted DNA can be used, with results delivered within 3 to 4 weeks. Our VIP mobile phlebotomy team visits your home from 8 AM to 11 PM using a certified cold‑chain kit. Once the specimen arrives at the ISO‑accredited laboratory, genomic DNA is enriched, sequenced on a next‑generation platform, and all findings are validated by Sanger sequencing before the final clinical report is issued.
3. Is the test covered by insurance and what is the exact cost?
The test costs 2,800 AED and many UAE insurers reimburse it when supported by a nephrologist’s referral and pre‑authorisation; direct billing verification is available through WhatsApp. We handle insurance coding using ICD‑10‑CM E26.81 and LOINC 69547‑9 to expedite claim approval. Patients are encouraged to send their insurance card copy via WhatsApp at +971 54 548 8731; our team responds within one business day with coverage details and any required co‑payment.
UAE Regulatory & Data Privacy Adherence
This test is performed under the regulatory oversight of the Dubai Health Authority (DHA Facility License No. 1143). Data handling and patient privacy are safeguarded in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent follow the provisions of Federal Decree‑Law No. 4 of 2016 on Medical Liability. Our laboratory holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139) and adheres to the highest standards of quality and confidentiality.
Clinical & Logistical Metadata
| Test Name | SLC12A5 Gene Bartter Syndrome Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Venous Blood, FTA Card, or Extracted DNA |
| Methodology Used | Next‑Generation Sequencing (Illumina) with Sanger Confirmation |
| ICD-10-CM Code | E26.81 |
| LOINC Code | 69547-9 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians